Cargando…

Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study

Objective: This study aimed to assess the association between treatment characteristics of prostaglandin E1 including initiation time and duration, maximal and cumulative doses, and adverse effects. Design: A retrospective cohort study in which medical records of neonates with duct-dependent lesions...

Descripción completa

Detalles Bibliográficos
Autores principales: Ofek Shlomai, Noa, Lazarovitz, Gilad, Koplewitz, Benjamin, Eventov Friedman, Smadar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528554/
https://www.ncbi.nlm.nih.gov/pubmed/37761532
http://dx.doi.org/10.3390/children10091572
_version_ 1785111276400148480
author Ofek Shlomai, Noa
Lazarovitz, Gilad
Koplewitz, Benjamin
Eventov Friedman, Smadar
author_facet Ofek Shlomai, Noa
Lazarovitz, Gilad
Koplewitz, Benjamin
Eventov Friedman, Smadar
author_sort Ofek Shlomai, Noa
collection PubMed
description Objective: This study aimed to assess the association between treatment characteristics of prostaglandin E1 including initiation time and duration, maximal and cumulative doses, and adverse effects. Design: A retrospective cohort study in which medical records of neonates with duct-dependent lesions were studied for treatment parameters and adverse effects. Multivariable logistic regression model was applied for testing the effect PGE1 variables on outcomes. Main outcome measures: The primary outcomes of this study were association of adverse effects of PGE1 treatment with maximal dose, cumulative dose, and treatment duration. The secondary outcomes included safety of feeding in infants treated with PGE1. Results: Eighty-two infants with duct-dependent lesions receiving PGE1 were included. Several infants who received early PGE1 treatment required ventilation support. Feeds were ceased more often as the cumulative dose and duration of PGE1 treatment increased. Gastrointestinal adverse effects were significantly associated with the cumulative dose of PGE1 and treatment duration. Apneas, hyperthermia, and tachycardia were associated with maximal dose. Our data did not demonstrate a difference in the incidence of NEC associated with characteristics of PGE1 treatment. Conclusion: Cumulative PGE1 dose is associated with gastrointestinal adverse effects in neonates. Lower doses should be considered in neonates expecting prolonged PGE1 treatment.
format Online
Article
Text
id pubmed-10528554
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105285542023-09-28 Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study Ofek Shlomai, Noa Lazarovitz, Gilad Koplewitz, Benjamin Eventov Friedman, Smadar Children (Basel) Article Objective: This study aimed to assess the association between treatment characteristics of prostaglandin E1 including initiation time and duration, maximal and cumulative doses, and adverse effects. Design: A retrospective cohort study in which medical records of neonates with duct-dependent lesions were studied for treatment parameters and adverse effects. Multivariable logistic regression model was applied for testing the effect PGE1 variables on outcomes. Main outcome measures: The primary outcomes of this study were association of adverse effects of PGE1 treatment with maximal dose, cumulative dose, and treatment duration. The secondary outcomes included safety of feeding in infants treated with PGE1. Results: Eighty-two infants with duct-dependent lesions receiving PGE1 were included. Several infants who received early PGE1 treatment required ventilation support. Feeds were ceased more often as the cumulative dose and duration of PGE1 treatment increased. Gastrointestinal adverse effects were significantly associated with the cumulative dose of PGE1 and treatment duration. Apneas, hyperthermia, and tachycardia were associated with maximal dose. Our data did not demonstrate a difference in the incidence of NEC associated with characteristics of PGE1 treatment. Conclusion: Cumulative PGE1 dose is associated with gastrointestinal adverse effects in neonates. Lower doses should be considered in neonates expecting prolonged PGE1 treatment. MDPI 2023-09-19 /pmc/articles/PMC10528554/ /pubmed/37761532 http://dx.doi.org/10.3390/children10091572 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ofek Shlomai, Noa
Lazarovitz, Gilad
Koplewitz, Benjamin
Eventov Friedman, Smadar
Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study
title Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study
title_full Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study
title_fullStr Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study
title_full_unstemmed Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study
title_short Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study
title_sort cumulative dose of prostaglandin e1 determines gastrointestinal adverse effects in term and near-term neonates awaiting cardiac surgery: a retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528554/
https://www.ncbi.nlm.nih.gov/pubmed/37761532
http://dx.doi.org/10.3390/children10091572
work_keys_str_mv AT ofekshlomainoa cumulativedoseofprostaglandine1determinesgastrointestinaladverseeffectsintermandneartermneonatesawaitingcardiacsurgeryaretrospectivecohortstudy
AT lazarovitzgilad cumulativedoseofprostaglandine1determinesgastrointestinaladverseeffectsintermandneartermneonatesawaitingcardiacsurgeryaretrospectivecohortstudy
AT koplewitzbenjamin cumulativedoseofprostaglandine1determinesgastrointestinaladverseeffectsintermandneartermneonatesawaitingcardiacsurgeryaretrospectivecohortstudy
AT eventovfriedmansmadar cumulativedoseofprostaglandine1determinesgastrointestinaladverseeffectsintermandneartermneonatesawaitingcardiacsurgeryaretrospectivecohortstudy